Quarterly infographic: MRSA, MSSA and Gram-negative bacteraemia and CDI, data up to October to December 2025
Updated 9 April 2026
Applies to England
Gram-negative bacteraemias (E. coli, Klebsiella spp. and P. aeruginosa)
Pseudomonas aeruginosa (P. aeruginosa) bacteraemia
October to December 2024: 8.0 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
October to December 2025: 8.5 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
Klebsiella spp. bacteraemia
October to December 2024: 23.4 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
October to December 2025: 24.1 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
Escherichia coli (E. coli) bacteraemia
October to December 2024: 73.2 out of every 100,000 persons developed an E. coli bacteraemia.
October to December 2025: 73.9 out of every 100,000 persons developed an E. coli bacteraemia.
Staphylococcus aureus (S. aureus) MRSA and MSSA bacteraemia and Clostridioides difficile (C. difficile) infections
Meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia
October to December 2024: 1.9 out of every 100,000 persons developed an MRSA bacteraemia.
October to December 2025: 1.8 out of every 100,000 persons developed an MRSA bacteraemia.
Meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia
October to December 2024: 24.2 out of every 100,000 persons developed an MSSA bacteraemia.
October to December 2025: 23.9 out of every 100,000 persons developed an MSSA bacteraemia.
Clostridioides difficile (C. difficile) infection
October to December 2024: 32.0 out of every 100,000 persons developed a C. difficile infection.
October to December 2025: 28.0 out of every 100,000 persons developed a C. difficile infection.